14 citations
,
September 2024 in “Arthritis & Rheumatology” In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.
April 2017 in “Journal of Investigative Dermatology” In this study of 40 dermatomyositis patients, most with moderate-severe disease at baseline improved over time in a polyphasic pattern, while those with mild disease often remained stable.
April 2018 in “Journal of Investigative Dermatology” This study suggests that for dermatomyositis patients with minimal skin disease activity, further improvement in cutaneous symptoms may not translate into better quality of life, highlighting a need to revise trial endpoints.
2 citations
,
January 2006 in “Technical report” This chapter reviews the development of skin-specific outcome instruments for autoimmune diseases like cutaneous lupus erythematosus and dermatomyositis, highlighting a need for a broader community-involved process across other diseases but reports no new results.
June 2024 in “British Journal of Dermatology” In this prospective observational study of 96 dermatomyositis patients, 47 showed scalp involvement, with significant symptoms like scalp inflammation, itching, and hair loss linked to myositis-specific antibodies. The study highlighted unique dermatopathological features in the scalp and emphasized the considerable morbidity caused by scalp dermatomyositis.